ACTC is just building a solid base after it's big huge multi million runs, imo.
ACTC could pop at anytime and it's very dangerous, imo, not to be heaily invested.
This stock will prove to be a once in a lifetime opportunity for investors, imo. So much points in that direction and their process has already shown to be effective in restoring sight in patients in other countries.
To me, owning this stock and GERN are no brainers.
They both have a ton of patents secured and that means residuals big time, not to mention their own individual potential here and in foreign countries, especially with europe approval apparentl about to happen soon.